Microbiome therapeutics developer Seres Therapeutics announced a further workforce reduction and a pause in its lead program following earlier layoffs and portfolio reassessment. The company is shifting resources after reprioritizing a Phase 2 study that it had previously funded for a bloodstream infection preventive treatment. Separately, the FDA cleared Optune Pax, Novocure’s tumor‑treating fields device for pancreatic cancer — a decision noted alongside multiple industry headcount moves. Seres framed its actions as part of a broader strategic reset to preserve runway and focus on development paths most likely to deliver value. The moves highlight persistent capital discipline across next‑generation therapeutic modalities and the recalibration companies undertake when lead programs encounter delays or resource constraints.